Media Articles Related to Maxalt-Mlt (Rizatriptan)
An Option in Migraine Prevention?
Source: Medscape NeurologyHeadlines [2014.03.05]
A recent study compares candesartan and propranolol for migraine prophylaxis.
Source: MedicineNet Chronic Pain Specialty [2014.02.24]
Title: Migraine Symptoms
Category: Doctor's & Expert's views on Symptoms
Created: 1/20/2005 12:00:00 AM
Last Editorial Review: 2/24/2014 12:00:00 AM
Source: MedicineNet Antiphospholipid Syndrome Specialty [2014.01.31]
Title: Migraine Headache
Category: Diseases and Conditions
Created: 12/31/1997 12:00:00 AM
Last Editorial Review: 1/31/2014 7:06:51 PM
Portable magnetic stimulation device 'effective' against migraines
Source: Headache / Migraine News From Medical News Today [2014.01.22]
According to The Migraine Trust, there are approximately 190,000 migraine attacks in the UK every day. Now, a new device that sends magnetic impulses to the brain could help combat the condition, and has been recommended as a treatment by the UK's National Institute for Health Care and Excellence.
Candesartan offers hope to migraine sufferers who currently get no relief from existing treatments
Source: Headache / Migraine News From Medical News Today [2014.01.15]
Candesartan is just as effective as the more commonly prescribed propranolol when it comes to preventing migraine attacks, according to a new study from St. Olavs Hospital in Trondheim, Norway and the Norwegian University of Science and Technology (NTNU).The researchers have also found that candesartan may work for patients who get no relief from propranolol.
Published Studies Related to Maxalt-Mlt (Rizatriptan)
Efficacy and tolerability of rizatriptan for the treatment of acute migraine in sumatriptan non-responders. [2011.05]
OBJECTIVE: The study was carried out to assess the efficacy and tolerability of rizatriptan orally disintegrating tablet (ODT) for treating acute migraine in patients who are non-responders to sumatriptan. BACKGROUND: Many migraineurs report dissatisfaction with sumatriptan efficacy. It is unclear whether sumatriptan 100 mg non-responders will respond to other triptans... CONCLUSION: Rizatriptan 10-mg ODT was superior to placebo at providing two-hour pain relief and two-hour pain freedom in the treatment of acute migraine in those who do not respond to sumatriptan 100 mg. Rizatriptan was generally well tolerated in this population.
A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraine. [2011.04]
The objective of this study was to assess patient satisfaction with acute treatment of migraine with frovatriptan or rizatriptan by preference questionnaire. 148 subjects with a history of migraine with or without aura (IHS 2004 criteria), with at least one migraine attack per month in the preceding 6 months, were enrolled and randomized to frovatriptan 2.5 mg or rizatriptan 10 mg treating 1-3 attacks...
Rizatriptan reduces vestibular-induced motion sickness in migraineurs. [2011.02]
A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo...
Efficacy of frovatriptan in the acute treatment of menstrually related migraine:
analysis of a double-blind, randomized, cross-over, multicenter, Italian,
comparative study versus rizatriptan. 
The objectives of this study are to assess the efficacy and safety of
frovatriptan, and rizatriptan in the subgroup of women with menstrually related
migraine of a multicenter, randomized, double blind, cross-over study. Each
patient received frovatriptan 2.5 mg or rizatriptan 10 mg in a randomized
sequence: after treating 3 episodes of migraine in not more than 3 months with
the first treatment, the patient had to switch to the other treatment...
A pilot study of rizatriptan and visually-induced motion sickness in migraineurs. [2009.08.06]
CONCLUSIONS: These pilot data suggest that rizatriptan does not consistently reduce visually-induced motion sickness in migraineurs. Rizatriptan may diminish motion sickness potentiation by cranial pain.
Clinical Trials Related to Maxalt-Mlt (Rizatriptan)
Study of Rizatriptan in the Treatment of Acute Attacks of Post-traumatic Headache in U.S. Military Troops [Recruiting]
A Study to Evaluate the Efficacy and Tolerability of Rizatriptan for Treatment of Acute Migraine in Children and Adolescents [Recruiting]
Rizatriptan in Acute Treatment of Migraine in Patients With Unilateral Trigeminal-Autonomic Symptoms. [Not yet recruiting]
Triptans are first choice drugs in the acute treatment of migraine and cluster headache.
However, while in cluster headache the response rate to subcutaneous sumatriptan is 96%,
around 30% of patients fail to respond to a particular triptan4. Nonresponse is likely to be
due to a variety of factors, including low and inconsistent absorption, inadequate dosing,
and variability in individual response5. Timing of administration is also a crucial issue.
In fact, an early treatment of the attack, when the pain is still mild, may increase the
responders rate by circumventing the development of cutaneous allodynia (expression of
central sensitization of pain pathway) during the course of the attack6,7.
Several studies have been performed in an attempt to genetically, psychologically and
clinically characterize the triptan responders but failed to provide conclusive results8-10.
Nevertheless, we suggested that the presence of UAs during the migraine attack might predict
a good response to triptans1,11. UAs are common in migraine patients. They have been
reported in almost one out of two migraineurs (45. 8%) attending a tertiary headache centre
and in more than one out of four (26. 9%) in a population-based study1,3. In an open study
with sumatriptan 50 mg performed on 72 migraine patients with UAs, we described pain relief
in 65. 3% of the patients at 1 h and in 81. 9% at 2 h, while pain-free in 30. 6% at 1 h and in
61. 1% at 2 h11. We hypothesized a large-scale recruitment of peripheral neurovascular
5-HT1B/1D receptors consequent to the activation of the trigeminal-autonomic reflex in such
patients. Our hypothesis has received further confirmation by the demonstration of higher
levels of calcitonin gene-related peptide, neurokinin A and vasoactive intestinal peptide
(the hallmark of the activation of the trigeminal autonomic reflex) in external jugular
blood in rizatriptan responders than in non-responders 12.
The investigators therefore postulate that migraineurs with UAs may respond better to
rizatriptan than "general" migraine population.
To evaluate the efficacy of rizatriptan 10 mg lyophilized wafer (MLT) compared to placebo in
the treatment of acute migraine in patients with unilateral autonomic symptoms (UAs:
unilateral lacrimation, eye redness, eyelid oedema, nasal congestion or rhinorrhoea, miosis
or ptosis, forehead or facial sweating) during the attack
Rizatriptan 10 MG RPD in the Treatment of Acute Migraine [Recruiting]
This is a multicentre, open label, prospective, randomized, two-attack study with active
comparator in patients reporting inadequate response to analgesics and/or triptans to
examine the efficacy of Rizatriptan 10 mg RPD in this group of patients.
Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response? [Recruiting]
Researchers want to learn about work productivity after treatment of a migraine headache
with your usual migraine medication as compared to your work productivity after treatment
During this research subjects will take Treximet to treat 3 workday migraine attacks. For a
second part of the research subjects will take their usual prescribed medication for 3
workday migraine attacks. The subjects will complete questionnaires after treating each
Reports of Suspected Maxalt-Mlt (Rizatriptan) Side Effects
Drug Ineffective (3),
Intestinal Ischaemia (2),
Abdominal Pain (1),
Cardiac Tamponade (1),
Sudden Death (1),
Abortion Spontaneous (1),
Drug Label Confusion (1), more >>